INNOVATE Corp. (VATE)
| Market Cap | 170.56M +107.5% |
| Revenue (ttm) | 1.25B +12.5% |
| Net Income | -64.00M |
| EPS | -4.84 |
| Shares Out | 13.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 34,916 |
| Open | 12.34 |
| Previous Close | 12.02 |
| Day's Range | 11.75 - 12.44 |
| 52-Week Range | 3.75 - 13.34 |
| Beta | 1.54 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 14, 2026 |
About VATE
INNOVATE Corp., through its subsidiaries, operates in infrastructure, life sciences, and spectrum areas in the United States. The company operates through the Infrastructure, Life Sciences, and Spectrum segments. The Infrastructure segment provides industrial construction, structural steel, and facility maintenance services, such as fabrication and erection of structural steel and heavy steel plate services, and large-diameter water pipes and water storage tanks; fabrication of trusses and girders; 3-D building information modeling and detailin... [Read more]
Financial Performance
In 2025, INNOVATE's revenue was $1.25 billion, an increase of 12.55% compared to the previous year's $1.11 billion. Losses were -$64.00 million, 78.8% more than in 2024.
Financial StatementsNews
INNOVATE Corp. to Report First Quarter 2026 Results on May 14th
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the first quarter 2026 on Thursday...
INNOVATE's Portfolio Company DBM Global to Pay Cash Dividend
NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that DBM Global Inc. (“DBMG”), a family of companies providing fully integrated s...
MediBeacon® Transdermal GFR Monitor and Reusable Sensor Receive CE Mark Under European Medical Device Regulation
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in...
INNOVATE Earnings Call Transcript: Q4 2025
Fourth quarter revenue surged 61.7% year-over-year, driven by infrastructure, while net loss narrowed. Life sciences and spectrum segments faced headwinds, but regulatory wins and backlog growth position the company for 2026 expansion.
INNOVATE Corp. Announces Fourth Quarter and Full Year 2025 Results
- Infrastructure: NYC and Western markets continue to demonstrate positive project momentum - - Life Sciences: R2 Secures 600‑System Commitment in China - - Spectrum: Recent network launches set to de...
INNOVATE Corp. to Report Fourth Quarter and Full Year 2025 Results on March 26th
NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the fourth quarter and full year 2...
Transdermal GFR Article Recognized as One of Five 2025 Editors' Choice Articles by Journal of the American Society of Nephrology (JASN)
NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in ...
MediBeacon® Next Generation TGFR™ System Receives FDA Approval
NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in ...
INNOVATE Earnings Call Transcript: Q3 2025
Q3 2025 revenue rose 43% year-over-year to $347.1M, led by infrastructure and life sciences growth, while net loss narrowed. DBM Global's backlog and R2's international sales surged, and MediBeacon secured key regulatory approval in China.
INNOVATE Corp. Announces Third Quarter 2025 Results
- Infrastructure: DBM Global delivers robust revenue growth, reinforcing market leadership - - Life Sciences: MediBeacon received regulatory approval to sell the Transdermal GFR System in China - - Sp...
INNOVATE Corp. to Report Third Quarter 2025 Results on November 12th
NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the third quarter 2025 on Wednesday...
MediBeacon receives regulatory approval to sell the Transdermal GFR System in China
NEW YORK, Oct. 21, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc., a medical technology company specializing in the advancement...
INNOVATE's Portfolio Company, R2, has Explosive Growth and Global Reach with Glacial® Skin Continuing to Redefine Aesthetic Innovation
NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) today announced that R2 Technologies, Inc. (“R2”), the innovators behind the breakthrough Glacial...
INNOVATE Earnings Call Transcript: Q2 2025
Q2 2025 saw a 22.7% revenue decline and a net loss of $22 million, driven by lower infrastructure and Spectrum results, partially offset by strong Life Sciences growth. Strategic refinancing extended debt maturities, while DBM Global and R2 maintained robust backlogs and positive outlooks.
INNOVATE Corp. Announces Second Quarter 2025 Results
- Infrastructure: Improved financial flexibility with recent refinancing transactions - - Life Sciences: R2 continuing to see significant year over year growth in system unit sales - - Spectrum: Launc...
INNOVATE Closes Indebtedness Refinancing Transactions
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) today announced that it has closed a series of previously announced indebtedness refinancing trans...
INNOVATE Announces Early Results of Exchange Offer of Senior Secured Notes and Solicitation of Consents and Extends Availability of Total Early Exchange Consideration
NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) today announced the early participation results as of 5:00 p.m., New York City time, on July 30, 2...
INNOVATE Corp. to Report Second Quarter 2025 Results on August 5th
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the second quarter 2025 on Tuesday,...
INNOVATE Launches Indebtedness Refinancing Transactions
$48.7 million privately negotiated convertible notes exchanges.$330 million exchange offer of senior secured notes and solicitation of consentsAgreement in principle to extend revolving credit agreeme...
DBM Global Enters Into an Amended and Restated Credit Agreement
NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that DBM Global Inc. (“DBMG”), has entered into an amended and restated credit agre...
INNOVATE Earnings Call Transcript: Q1 2025
Q1 2025 revenue fell 13% year-over-year to $274.2 million, with adjusted EBITDA at $7.2 million and a net loss of $24.8 million. Infrastructure backlog reached $1.4 billion, life sciences saw strong R2 growth, and Spectrum advanced new tech initiatives.
INNOVATE Corp. Announces First Quarter 2025 Results
- Infrastructure: DBM Global first quarter revenue of $264.9 million - - Life Sciences: MediBeacon ® Transdermal GFR (“TGFR”) System Received FDA Approval to Assess Kidney Function - - Spectrum: Expec...
INNOVATE Corp. to Report First Quarter 2025 Results on May 6th
NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the first quarter 2025 on Tuesday,...
INNOVATE Earnings Call Transcript: Q4 2024
Q4 2024 revenue fell 34.5% year-over-year to $236.6M, with adjusted EBITDA at $15M. Life sciences and Spectrum segments saw strong growth, while infrastructure faced project delays but maintained a robust backlog. Total debt was reduced by $54.5M year-over-year.
INNOVATE Corp. Announces Fourth Quarter and Full Year 2024 Results
- Infrastructure: DBM Global fourth quarter revenue of $225.7 million - - Life Sciences: MediBeacon ® Transdermal GFR (“TGFR”) system received FDA approval to assess kidney function - - Spectrum: Broa...